Document is current
Any future updates will be listed below
-
Authors
Pabon, Elisa
Baglot, Samantha L.
Eversole, Alisha
Fong, Timothy
Hampilos, Katherine
Hilger, Anna
Lake, Stephanie
Murray, Conor H.
Arout, Caroline A.
Haney, Margaret
Tran, Adren
Torrens, Alexa
Piomelli, Daniele
Cooper, Ziva D.
-
Funding
Funding for this research was provided by:
Charles R. Drew University of Medicine and Science
- License Information
-
More Information
Article History
Received: 6 November 2025
Accepted: 8 April 2026
First Online: 21 April 2026
Declarations
:
: This study was approved by the Institutional Review Board (IRB) of the University of California, Los Angeles (IRB-19-0876) and was conducted in accordance with ethical standards established in the Helsinki Declaration. Participants provided written informed consent for participation in the study.
: NCT04385082.
: Funding source: US National Institute on Drug Abuse (R01DA047296, P50DA044118), UCLA Clinical and Translational Science Institute NCATS (UL1TR001881), and the Semel Charitable Foundation. EP was supported by the US National Institute of General Medical Sciences IRACDA at UCLA (K12GM106996). AE was support by the US National Institute on Drug Abuse (T32DA024635). SL was supported by the Canadian Institutes of Health Research (CIHR) Banting Postdoctoral Fellowship. SB was supported by a CIHR Fellowship. Outside of this work, ZDC reports receiving study drug from Canopy Growth Corp and True Terpenes, and study-related materials from Storz & Bickel. ZDC’s research is funded by grants from the National Institute on Drug Abuse, National Center for Complementary and Integrative Health, California Department of Cannabis Control, Center for Medicinal Cannabis Research, and the California Highway Patrol. MH is a stockholder of and on the scientific advisory board for PleoPharm.
